Ocugen on Friday said that the US Food and Drug Administration (FDA) has declined to issue an emergency use authorisation (EUA) for Covaxin — the Covid-19 vaccine developed by its Indian partner Bharat Biotech — for use in individuals aged 2 to 18 years.
“The US FDA, at this time, has declined to issue an EUA for Covaxin for active immunisation to prevent Covid-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age,” the company said in a statement on Friday.
Ocugen intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of Covaxin, it added in the statement.
Ocugen is a clinical stage biopharmaceutical company which is co-developing Bharat Biotech’s Covaxin vaccine candidate for Covid-19 in the US and Canadian markets.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.